PALBOCICLIB, Zoladex 3,6 mg implante en jeringa precargada, AZD8421, PALBOCICLIB, AZD8421, PALBOCICLIB, PALBOCICLIB, RIBOCICLIB, Camizestrant, PALBOCICLIB, ABEMACICLIB, PALBOCICLIB, ABEMACICLIB, AZD8421, ABEMACICLIB
CYCAD-1(D8470C00001)
Phase 2 small_molecule active
Quick answer
PALBOCICLIB, Zoladex 3,6 mg implante en jeringa precargada, AZD8421, PALBOCICLIB, AZD8421, PALBOCICLIB, PALBOCICLIB, RIBOCICLIB, Camizestrant, PALBOCICLIB, ABEMACICLIB, PALBOCICLIB, ABEMACICLIB, AZD8421, ABEMACICLIB for Patients with ER+ HER2- advanced breast cancer and patients with high-grade serious ovarian cancer (HGSOC) is a Phase 2 program (small_molecule) at AstraZeneca AB with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AstraZeneca AB
- Indication
- Patients with ER+ HER2- advanced breast cancer and patients with high-grade serious ovarian cancer (HGSOC)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active